Cytokine expression in response to root repair agents.

Area of Science:

• Biomaterials Science
• Immunology
• Regenerative Medicine

Background:

• Bone regeneration relies on a complex interplay of cytokines and cellular signaling pathways.
• Biomaterials like MTA, Geristore®, and Emdogain® are used in bone repair, but their immunomodulatory effects require detailed investigation.
• Understanding the inflammatory profiles of these agents is crucial for optimizing clinical outcomes in bone defect healing.

Purpose of the Study:

• To comparatively evaluate the mRNA expression of key pro-inflammatory and anti-inflammatory cytokines (TNF-α, IL-6, IFN-γ, TGF-β, IL-4, IL-10) and bone remodeling markers (RANKL, RANK, OPG) in mouse calvarial bone defects treated with MTA, Geristore®, and Emdogain®.
• To elucidate the distinct immunomodulatory effects of these three bone repair agents.
• To provide insights into the differential biological responses elicited by MTA, Geristore®, and Emdogain® at the cellular level.

Main Methods:

• Surgical creation of calvarial bone defects in C57BL/6 mice.
• Application of MTA, Geristore®, or Emdogain® into the bone defects.
• Quantification of mRNA expression for selected cytokines and bone remodeling markers using real-time PCR at 14 and 21 days post-treatment.
• Statistical analysis using nonparametric methods (Mann-Whitney and Kruskal-Wallis tests).

Main Results:

• MTA and Emdogain® significantly increased the expression of RANKL, RANK, and OPG from day 14 to 21, indicating modulation of bone remodeling.
• Emdogain® significantly upregulated TNF-α and other pro-inflammatory/regulatory cytokines (IL-6, TGF-β, IL-4, IFN-γ), while Geristore® downregulated TNF-α, IL-6, TGF-β, and IL-4.
• Geristore® did not significantly alter the basal expression of RANKL, RANK, or OPG during the evaluation period.

Conclusions:

• MTA and Emdogain® induce distinct inflammatory responses, with Emdogain® showing a more pronounced pro-inflammatory profile early on and an anti-inflammatory shift later.
• Geristore® appears to have a minimal inflammatory impact compared to MTA and Emdogain®.
• The choice of bone repair agent should consider the desired inflammatory and regenerative response, potentially guided by the specific clinical context, such as root resorption diagnosis.